دورية أكاديمية
أعرض في EDS

Effects of calcium channel blockers in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Effects of calcium channel blockers in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis.
المؤلفون: Fukuta H; Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Goto T; Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Kamiya T; Department of Medical Innovation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
المصدر: PloS one [PLoS One] 2024 Aug 19; Vol. 19 (8), pp. e0307258. Date of Electronic Publication: 2024 Aug 19 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Heart Failure*/drug therapy , Heart Failure*/physiopathology , Calcium Channel Blockers*/therapeutic use , Stroke Volume*/drug effects , Systematic Reviews as Topic* , Meta-Analysis as Topic*, Humans ; Prognosis
مستخلص: Background: Nearly half of patients with heart failure (HF) have preserved ejection fraction (EF) and the mortality and morbidity of patients with HF with preserved EF (HFpEF) are high. Patients with HFpEF are often elderly and their primary chronic symptom is severe exercise intolerance. Due to the frequent coexistence of hypertension in HFpEF patients, the use of anti-hypertensive medications is common in their treatment. While many cohort studies and several randomized controlled trials (RCTs) have examined the effectiveness of various anti-hypertensive drugs such as beta-blockers and renin-angiotensin system inhibitors in HFpEF, the role of calcium channel blockers (CCBs) remains uncertain. Despite several RCTs and cohort studies exploring the effects of CCBs on prognosis and exercise capacity in HFpEF patients, the findings have been inconsistent, likely due to limited statistical power and/or variations in study design. Therefore, our aim is to conduct a systematic review and meta-analysis of studies on the effects of CCBs in these patients.
Methods: This meta-analysis will include RCTs and cohort studies on the effect of CCBs in HFpEF patients. Information of studies will be collected from PubMed, Web of Science, and Scopus. The primary outcome of interest will be prognosis. The secondary outcome of interest will be exercise capacity.
Discussion: Synthesizing our meta-analytical results with expert consensus could contribute to the formulation of updated clinical guidelines. Our systematic review and meta-analysis will provide directions for future research on the use of CCBs in HFpEF patients.
Systematic Review Registration: INPLASY202430097.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Fukuta et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Circ Res. 2019 May 24;124(11):1598-1617. (PMID: 31120821)
J Am Coll Cardiol. 2000 Apr;35(5):1245-55. (PMID: 10758967)
Heart Fail Rev. 2021 Jan;26(1):165-171. (PMID: 32743714)
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. (PMID: 12091180)
Eur J Prev Cardiol. 2022 Jul 20;29(9):1343-1351. (PMID: 35015840)
ESC Heart Fail. 2017 Nov;4(4):402-408. (PMID: 28869332)
Syst Rev. 2015 Jan 01;4:1. (PMID: 25554246)
Eur J Heart Fail. 2020 Jun;22(6):1009-1018. (PMID: 32150314)
Eur J Heart Fail. 2016 Jan;18(1):54-65. (PMID: 26634799)
BMC Med Res Methodol. 2021 Jun 15;21(1):123. (PMID: 34130658)
Eur Heart J. 2023 Oct 1;44(37):3627-3639. (PMID: 37622666)
PLoS One. 2014 Mar 05;9(3):e90555. (PMID: 24599093)
Circ J. 2010 Jul;74(7):1364-71. (PMID: 20501958)
N Engl J Med. 2006 Jul 20;355(3):251-9. (PMID: 16855265)
Circulation. 2022 May 3;145(18):e895-e1032. (PMID: 35363499)
N Engl J Med. 2014 Apr 10;370(15):1383-92. (PMID: 24716680)
Int J Cardiol. 2017 Feb 1;228:4-10. (PMID: 27863360)
Am J Cardiovasc Drugs. 2007;7 Suppl 1:17-23. (PMID: 19845073)
N Engl J Med. 1982 Mar 25;306(12):699-705. (PMID: 7038483)
Clin Cardiol. 2023 Aug;46(8):845-852. (PMID: 37272188)
N Engl J Med. 2019 Oct 24;381(17):1609-1620. (PMID: 31475794)
J Clin Epidemiol. 2011 Apr;64(4):380-2. (PMID: 21185693)
Int J Clin Pract. 2002 Jan-Feb;56(1):57-62. (PMID: 11831838)
Circ Res. 2022 Jun 10;130(12):1906-1925. (PMID: 35679364)
Heart Fail Rev. 2017 Nov;22(6):775-782. (PMID: 28702858)
Am J Cardiol. 1990 Oct 15;66(12):981-6. (PMID: 2220622)
Int J Cardiol. 2014 Feb 15;171(3):331-7. (PMID: 24439772)
Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77. (PMID: 12524257)
Am J Cardiol. 1977 May 4;39(5):697-700. (PMID: 857630)
Heart Fail Rev. 2021 Nov;26(6):1477-1484. (PMID: 32562021)
BMJ. 2011 Oct 18;343:d5928. (PMID: 22008217)
Eur J Heart Fail. 2023 Dec;25(12):2202-2214. (PMID: 37771260)
JAMA. 2002 Nov 6;288(17):2144-50. (PMID: 12413374)
Circulation. 2005 Jul 19;112(3):357-63. (PMID: 16009792)
Circ Heart Fail. 2014 Nov;7(6):945-52. (PMID: 25296862)
J Am Coll Cardiol. 1999 Jun;33(7):1948-55. (PMID: 10362198)
Am Heart J. 1992 Oct;124(4):1017-25. (PMID: 1529875)
المشرفين على المادة: 0 (Calcium Channel Blockers)
تواريخ الأحداث: Date Created: 20240819 Date Completed: 20240819 Latest Revision: 20240822
رمز التحديث: 20240822
مُعرف محوري في PubMed: PMC11332996
DOI: 10.1371/journal.pone.0307258
PMID: 39159218
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0307258